Navigation Links
Bayer HealthCare Announces Collaboration with the University of Texas MD Anderson Cancer Center
Date:12/11/2013

WHIPPANY, N.J., Dec. 11, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the company has signed a master agreement for the performance of clinical trials with the Houston-based University of Texas MD Anderson Cancer Center.

The agreement aims to bolster ongoing and future collaborative clinical programs in oncology and bring new cancer treatments to patients. The growing oncology franchise of Bayer HealthCare explores specific treatment approaches for various tumors, including such common types of cancer as prostate, colorectal and breast cancer, as well as rarer forms like kidney, liver and thyroid cancer. MD Anderson Cancer Center ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention.

The two organizations, as part of the agreement, have formed a joint committee comprising clinicians and scientists from Bayer HealthCare's sites in Berlin, Germany and Whippany, New Jersey and from MD Anderson in Houston, Texas, to plan and conduct clinical trials with investigational anti-cancer agents developed by Bayer HealthCare.

"We are looking forward to collaborating with MD Anderson and believe the collaboration will help to bring promising new cancer treatments to patients," noted Professor Andreas Busch, Head of Global Drug Discovery and Member of the Executive Committee of Bayer HealthCare. "MD Anderson has outstanding programs that integrate patient care, research and prevention. The alliance is another significant step underlining our focus in oncology."

"We look forward to working with our Bayer HealthCare colleagues to translate scientific discoveries into novel cancer therapeutics," said Professor Aman Buzdar, MD, Vice President, Clinical Research. "MD Anderson's deep expertise and knowledge in oncology complement Bayer HealthCare's decades of experience in pharmaceutical development."

As part of the company's overall innovation strategy, Bayer HealthCare is expanding its collaborative relationships with academia and life science firms all over the world.

"Bayer is committed to bringing collaborative leadership to life by fostering partnerships with world renowned research centers such as MD Anderson," said Kemal Malik, M.D., Head of Global Development, Bayer HealthCare. "The partnership will bring together thought-leading scientists who will focus on improving the understanding of the biological mechanism of cancer to help identify patients who are likely to respond to specific treatments." 

About Oncology at Bayer HealthCare 
Bayer HealthCare is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer HealthCare now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company's approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.

About Bayer HealthCare Pharmaceuticals Inc. 
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Medical Care, and Pharmaceuticals divisions.  As a specialty pharmaceutical company, Bayer HealthCare provides products for General Medicine, Hematology, Neurology, Oncology and Women's Healthcare.  The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

Forward-Looking Statements
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.      

Intended for U.S. Media Only


'/>"/>
SOURCE Bayer HealthCare
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
2. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
3. Bayer Partnership Delivers Industry-First Dose Management Offering
4. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
5. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
6. Bayer Submits New Drug Application for Regorafenib for the Treatment of Gastrointestinal Stromal Tumors (GIST)
7. Hagens Berman Sobol Shapiro LLP and Douglas & London P.C. Announce Proposed Class Action Settlement in Bayer Combination Aspirin Products Litigation
8. MediSapiens sapprête à fournir à Bayer HealthCare Pharmaceuticals une nouvelle application informatique en nuage pour analyser et visualiser les données génomiques multidimensionnelles
9. MediSapiens liefert neue Cloud-Computing-App zur Analyse und Visualisierung multidimensionaler Genomdaten an Bayer HealthCare Pharmaceuticals
10. MediSapiens to Provide Bayer HealthCare Pharmaceuticals With a New Cloud Computing Application to Analyze and Visualize Multi-Dimensional Genomics Data
11. Bayers Second Annual Virtual Walk for Hemophilia Raises Funds, Generates Excitement in the Hemophilia Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2020)... ... 04, 2020 , ... Help.org , a trusted online resource for individuals ... in Akron, Ohio for 2020. The informational guide recognizes the top 18 rehab facilities ... recent studies , drug overdose is the leading cause of death among people ...
(Date:8/5/2020)... , ... August 04, 2020 , ... ... pathology therapy services vital to their health and quality of life unless Congress ... the American Speech-Language-Hearing Association (ASHA) warns today. , At issue ...
(Date:8/3/2020)... ... August 03, 2020 , ... Seattle’s ... been reached, to amend and restate IDRI’s license with Immune Design, a wholly ... Canada). Under the amendment, the parties have agreed to modify the licensed fields ...
Breaking Medicine Technology:
(Date:8/12/2020)... (PRWEB) , ... August 12, 2020 , ... ... 5000 list, the most prestigious ranking of America’s fastest-growing private companies. , ... represents a unique look at the most successful companies within the American economy’s ...
(Date:8/11/2020)... , ... August 11, 2020 , ... ... living with memory impairment, has announced the Best Memory Care Facilities in San ... to experts, facility features and amenities. , According to the Alzheimer’s ...
(Date:8/11/2020)... ... August 11, 2020 , ... ... is offering a new line of sanitizers that are fragrance-free and gentle on ... have an unpleasant odor or potentially dangerous levels of toxic chemicals. This is ...
(Date:8/11/2020)... ... 11, 2020 , ... NeoTract, a wholly owned subsidiary of ... today announced that Sean Delair, M.D., Tennessee Urology in Powell, TN, has been ... has achieved a high level of training and experience with the UroLift® System ...
(Date:8/7/2020)... RAPIDS, Mich. (PRWEB) , ... August 07, 2020 , ... ... during the COVID-19 pandemic during this past spring, The Bengtson Center team decided to ... who may be seen on an individual basis. With the offices now open again, ...
Breaking Medicine News(10 mins):